Custom-Made cancer vaccine shows promise in advanced tumors
NCT ID NCT06682117
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized vaccine created from a patient's own immune cells (dendritic cells) that are trained to attack unique markers on their tumor. It is for people with advanced solid tumors who have not responded to standard treatments. The main goal is to check safety and see if the vaccine can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can laser or ozone therapy better soothe cancer-related mouth pain? a head-to-head comparison
- Open-Face mask may improve comfort and accuracy in head and neck cancer radiation
- Can a radioactive tracer reveal whether immunotherapy is working?
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?